Chief Scientific Officer
Transformational chief scientific officer and collaborative leader with deep experience in driving innovative drug discovery approaches and rapidly constructing and cultivating high-performance teams. Shaped diverse platform approaches to develop anti-infective, microbiome, synthetic biology, and genetics- and genomics-driven drug candidates for treatment of infectious diseases, rare genetic diseases and inflammatory disorders. More recent biology target expansion has crossed the host-pathogen interface to uncover mechanisms driving and exacerbating chronic inflammatory diseases. Strategically selected and employed technologies to accomplish drug discovery goals and shorten timeline for bringing development candidates to human clinical trials. Facilitated organizational evolution by managing group reorganizations, securing investor funding, and expanding therapeutic portfolios to support strategic direction.